Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.40 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.40 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11895902 | 0.95 | MEN1 (0.45) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL27824295 | 0.88 | MEN1 (0.46) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL8666244 | 0.88 | MEN1 (0.46) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL5981757 | 0.86 | TPSAB1 (0.55) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL1006590 | 0.86 | MEN1 (0.46) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL607492 | 0.84 | MEN1 (0.42) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL15513572 | 0.84 | MEN1 (0.50) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL12989005 | 0.83 | MEN1 (0.41) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL8529057 | 0.83 | MEN1 (0.41) | MEN1GAAKMT2ATPSAB1TPSD1 | |
| SCHEMBL7280716 | 0.83 | MEN1 (0.41) | MEN1GAAKMT2ATPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119390613-A | Synthesis method of arginine derivative containing Cbz/Boc protecting group | 浙江工业大学 | 2025-02-07 | — | — | CN | claimed |
| JP-11228537-A | — | — | None | — | — | JP | disclosed |
| CN-119390613-A | Synthesis method of arginine derivative containing Cbz/Boc protecting group | 浙江工业大学 | 2025-02-07 | — | — | CN | disclosed |
| CN-114907241-B | Guanidine compound containing fluorosulfonyl group, and preparation method and application thereof | 中宏鑫投资控股(深圳)有限公司 | 2024-05-17 | — | — | CN | disclosed |
| WO-2023146892-A1 | BIPHENYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS | PARION SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3898629-B1 | IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| CN-114907241-A | Fluorine sulfonyl-containing guanidine compound and preparation method and application thereof | 中国科学院上海有机化学研究所 | 2022-08-16 | — | — | CN | disclosed |
| US-11390604-B2 | Imidazole-pyrazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-07-19 | — | — | US | disclosed |
| US-11285165-B2 | Selective high-affinity polydentate ligands and methods of making such | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) | 2022-03-29 | — | — | US | disclosed |
| US-7291616-B2 | Aryl triazines as LPAAT-β inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2007-11-06 | — | — | US | disclosed |
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | CELL THERAPEUTICS, INC. (US) | 2003-08-14 | — | — | US | disclosed |
| WO-2003037346-A1 | 6-PHENYL-N-PHENYL-(1,3,5) -TRIAZINE-2,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOPHPHOSPHATIDIC ACID ACYLTRANSFERASE BETA (LPAAT-BETA) INHIBITORY ACTIVITY FOR USE IN THE TREATMENT OF CANCER | CELL THERAPEUTICS, INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| JP-H11228537-A | INDOXYL-AMINO ACID ESTER OR INDOXYL-PEPTIDE ESTER AND ITS PRODUCTION AND TRYPSIN SUBSTRATE USING THE SAME | KDK CORP | 1999-08-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | MEN1 856/4885GAA 1186/4885KMT2A 3310/4885 |
| US-11390604-B2 | Imidazole-pyrazole derivatives | F12, CYP3A7, NLRP3 | MEN1 872/4885GAA 1901/4885KMT2A 4484/4885 |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | MEN1 856/4885GAA 1186/4885KMT2A 3310/4885 |
| US-11285165-B2 | Selective high-affinity polydentate ligands and methods of making such | CD44, FCGR3B, FCGR2A | MEN1 1828/4885GAA 4122/4885KMT2A 3857/4885 |
| US-20230141403-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | XDH, MYD88, IKZF3 | MEN1 298/4885GAA 2186/4885KMT2A 3088/4885 |
| US-20030153570-A1 | Aryl triazines as LPAAT-SS inhibitors and uses thereof | LPCAT3, LPCAT1, PLAAT2 | MEN1 3342/4885GAA 1093/4885KMT2A 252/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | MEN1 919/4885GAA 1269/4885KMT2A 3307/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | MEN1 1429/4885GAA 1126/4885KMT2A 2990/4885 |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | MEN1 724/4885GAA 1417/4885KMT2A 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.